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Abstract
Objectives With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified 
and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection 
of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary 
biomarkers in predicting response to intravesical Bacillus Calmette–Guerin (BCG) therapy.
Methods and materials A medline/pubmed© literature search was performed. The performance of commercially available 
and investigational biomarkers has been reviewed. End points were cancer detection (recurrence), cancer progression, and 
response to BCG therapy.
Results The performance requirements for biomarkers are variable according to the clinical scenario. The clinical role 
of urinary biomarkers in the follow-up of non-muscle invasive BCa patients remains undefined. The FDA-approved tests 
provide unsatisfactory sensitivity and specificity levels and their use is limited. Fluorescence in situ hybridization (FISH) 
has been shown to be useful in specific scenarios, mostly as a reflex test and in the setting of equivocal urinary cytology. 
FISH and immunocytology could conceivably be used to assess BCG response. Recently developed biomarkers have shown 
promising results; upcoming large trials will test their utility in specific clinical scenarios in a manner similar to a phased 
drug development strategy.
Conclusions Current commercially available urinary biomarker-based tests are not sufficiently validated to be widely used 
in clinical practice. Several novel biomarkers are currently under investigation. Prospective multicenter analyses will be 
needed to establish their clinical relevance and value.
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Introduction
Bladder cancer (BCa) has the highest lifetime cost per patient 
of all cancers [1]. This is mainly due to the high recurrence 
rate and the consequent need for close, long-term follow-up 
based on the patient’s risk profile. Follow-up generally consists 
of regular surveillance cystoscopy and voided urine cytology 
with periodic upper urinary tract imaging [3]. The intensity 
and invasiveness of these tests can lead to morbidity, com-
promise in patients’ quality of life, and financial burden [4].
Use of urinary biomarkers could obviate these and poten-
tially either detect disease recurrence before it becomes visu-
ally apparent or exclude its presence. Unfortunately, the most 
used urinary test, cytology, suffers from insufficient reproduc-
ibility and robustness to suffice for utility in various clinical 
scenarios such as surveillance of the most common type of 
BCa (low-grade NMIBC) [5, 6]. Recent multicenter studies 
have also shown a lower sensitivity of cytology for high-grade 
cancer compared to historical data [7, 8]. Urinary biomarkers 
in the surveillance setting have three aims: to reduce the fre-
quency of invasive testing while still detecting early disease 
recurrence (Rec), to exclude the presence of recurrent disease 
and to detect progression (Prog) in non-muscle invasive blad-
der cancer (NMIBC) patients and predicting response to thera-
pies [9].
Several urinary biomarkers have been investigated accord-
ing to these objectives. Six of them have been approved by the 
FDA in the follow-up of NMIBC patients. However, the trials 
designed to determine their accuracy were not sufficient to 
determine their clinical utility. Low positive predictive values 
due to insufficiently robust specificity have undermined the 
ability to use them in clinical practice in most settings. Actu-
ally, despite urologists can be considered early adopters of 
new technologies (in this case, of new markers), the ability to 
maintain innovations is influenced from performances, impact 
on decision-making and costs [10]. As such, the use of urinary 
markers in the surveillance of NMIBC remains limited. To 
overcome these limitations, a new generation of biomarkers 
has been developed and is currently under investigation, with 
initial results reported as “promising”.
We sought to review the current literature on urinary bio-
markers used in the surveillance of NMIBC patients to discuss 
recent findings through a clinical lens and to create an up-to-
date reference point.
Methods and materials
A medline/pubmed© literature search was performed with 
different combinations of the terms “urinary biomarker”, 
“bladder cancer”, “superficial bladder cancer”, “non-mus-
cle invasive bladder cancer”, “surveillance”, “follow-up”, 
“performance”, and “BCG response”. No time period 
restriction was set. Original articles, reviews and editori-
als were selected based on their clinical relevance. Cited 
references from selected articles were analyzed to find and 
include significant papers missed by our search. The perfor-
mance of commercially available and investigational bio-
markers was reviewed. End points were cancer detection 
(Rec), cancer Prog, and response to BCG therapy.
Performance criteria desired and urinary 
markers evaluation according to quality 
of research: general considerations
The performance of biomarkers depends upon their sensi-
tivity, specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV). A marker’s predictive value is 
influenced by the prevalence of the disease in the population. 
In tumors, the value of urinary markers according to their 
sensitivity and specificity varies according to specific clini-
cal scenarios and can influence their predictive value. This 
should be taken into account during the evaluation process.
Furthermore, an evaluation of biomarkers should not 
overlook their “clinical utility rating”. Since the develop-
ment phases for biomarkers discovery and application 
are not dissimilar to those of therapeutic drugs, a phased 
approach evaluation scale has been proposed [11, 12]. This 
consists of a sequence of consecutive phases that can be 
summarized as: (1) preclinical exploratory studies; (2) assay 
development (phase 0); (3) small retrospective series (phase 
I); (4) independent validation of the accuracy in larger series 
(phase II); (5) external validation in retrospective/prospec-
tive multicenter series and prospective clinical trials (phase 
III) and (6) post-approval reports (phase IV) [13]. Based 
on this scale, it is possible to evaluate the current status of 
biomarker development processes to understand their role 
in clinical practice.
To date, five urinary tests (NMP22 test kit, NMP22 Blad-
derChek Test, BTA TRAK, BTA stat, and UroVysion) have 
been approved by the US Food and Drug Administration 
(FDA) in the detection and surveillance setting, while the 
uCyt + test is only approved in the follow-up of NMIBC 
patients. However, none of them have been broadly imple-
mented in clinical practice. Furthermore, none are recom-
mended in international guidelines [3, 4, 14]. Numerous 
novel biomarkers have been tested and are currently under 
development (phase I–II–III). Thus far, they have not been 
approved by the FDA or other regulative agencies. How-
ever, one must also note that many markers are commercially 
available with no goal to become FDA-approved. There is 
no requirement to seek FDA approval for use in the US. 
While it can help with reimbursement from some insurance 
companies, it does limit the ability to modify the marker by 
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either using additional markers in a panel or changing cut-
points. If the marker is already FDA-approved, then all the 
studies need to be repeated if the marker is modified even 
in the slightest. This is a roadblock for refining some of the 
already approved markers.
Urinary biomarkers for the surveillance 
of bladder cancer patients
Performance criteria desired
The performance criteria for urine markers highly depend on 
the clinical question to be answered. As with any test (labo-
ratory, imaging, etc.), the result of the test depends heavily 
on the clinical setting. Since the goals for a marker may be 
different in a low- vs. high-risk patient or in first vs. fifth 
year of surveillance, the likelihood of cancer (prevalence) 
and projected use of the urine marker should impact the type 
of marker and designed performance characteristics.
For example, if the goal is to avoid a cystoscopy when a 
marker is negative, the marker has to have a very high NPV. 
This is especially important in high-grade disease, where 
a missed cancer due to a negative marker test could have 
a major impact on disease progression. On the other side, 
markers with a high sensitivity are needed if the tests are 
used in a setting where an improved detection is needed 
such as in patients at 3 months after initial TURBT or in 
those with high-risk disease. There is broad recognition from 
studies on enhanced cystoscopy that white-light cystoscopy 
alone can miss disease, especially carcinoma in situ (CIS) 
so that a marker can help to identify missed cancer. Most 
marker studies were not designed to biopsy patients with 
normal cystoscopy, but an abnormal biomarker. As such, 
it is not clear if an abnormal marker in the setting of a nor-
mal white-light cystoscopy implies the presence of cancer. 
Patients with a positive cytology are usually taken to the 
operating room for a biopsy and selective upper tract cytol-
ogy, but that is not the case for positive markers. The con-
cept of anticipatory positives is based on the concern that a 
marker can detect disease before it is visualized, but it is still 
not clear if this is clinically useful information [15].
Finally, predicting response to intravesical therapies 
such as BCG requires different characteristics than simply 
an improved detection and the role of urinary biomarkers in 
this setting is unclear so far.
Urinary markers rated according to quality 
of research—according to phased approach
The performances of phase III–IV and phase II–III markers 
are summarized in Table 1.
Phase III–IV markers
Nuclear matrix protein 22 (NMP22) Nuclear matrix proteins 
are a structural part of the cell nucleus and provide support 
for the nuclear shape. A member of this family, NMP22, has 
been found to be elevated in malignant urothelial cells com-
pared to normal urothelium, and is released in the urine as 
the result of apoptosis. Two assays have been developed to 
detect the presence of NMPs in urine. The first, NMP22BC 
is a quantitative Elisa test; the NMP22 BladderChek is a 
qualitative point-of-care (POC) test [16].
Table 1  Summary of phase II–IV and phase II–III marker’s performances and their actual role in clinical practice for the surveillance of non-
muscle invasive bladder cancer patients
PPV positive predictive value, NPV negative predictive value





PPV (range, %) NPV (range, %) Actual role in clinical  practicea
NMP22 BladderChek 11–85.7 77–100 18.2–100 61.9–93.9 –
NMP22 24–81 49–100 31–100 60–91 –
BTA STAT 40–72 29–96 40–88 38–76.9 –
BTA Trak 50–62 68–87 45.4 88.4 –
ImmunoCyt 50–85 62–86 26–72 81–93 Could be used as reflex test in 
case of unsuspicious cystos-
copy and equivocal/atypical 
cytology
UroVysion 13–100 63–100 21–83 67.9–100 Could be used as reflex test in 
case of unsuspicious cystos-
copy and equivocal/atypical 
cytology
Cxbladder monitor 91–93 – – 96–97 –
Bladder cancer (UBC) test 12–80 77.3–97 65.5–71.4 73.9–76.6 –
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Independent of the type of test (qualitative or quantita-
tive), a pooled analysis of seven studies with 4384 patients 
with previously treated BCa showed a sensitivity and spec-
ificity across all studies of 69% (range 50–85%) and 81% 
(range 46–93%), respectively [17].
Fourteen studies reported the performance of NMP22 
BladderChek while 15 reported on NMP22BC (Table 2). 
According to a phased approach, NMP22 tests reached 
phase III (independent confirmation studies). Recently, 
four marker-comparison studies have been published, 
reporting low sensitivity rates of the qualitative test in 
detecting Rec (11–58%) [7, 18–20]. In contrast, the 
quantitative NMP22BC test is measured on a continuous 
scale and then transformed into a dichotomous variable 
by choosing a cut-off threshold (estimated at 10 ng/mL). 
From a biologic point of view, the use of a cut-off does 
not make much sense in the context of the continuity that 
the appearance of this marker represents, and therefore, 
generally leads to lower overall accuracy. Indeed, NMP22 
BladderChek had a very poor sensitivity level for detecting 
Rec (26%), which only slightly outperformed that obtained 
with NMP22BC in the same population [7]. However, in a 
decision curve analysis, NMP22 was associated with onco-
logical outcomes; it has been suggested that this test could 
be useful in decision-making between an immediate and 
delayed cystoscopy, depending on a clinician’s threshold 
to perform a surveillance cystoscopy [21].
The predictive value of the tests has also been evalu-
ated with discordant results. Only few studies have found 
an association between NMP22 and future events such as 
Rec and Prog [19, 21, 22].
Bladder tumor antigen (BTA) Bladder tumor antigen 
(BTA) tests detect the presence of basement membrane 
factors in the urine, which are released from tumor cells 
during stromal invasion. The BTA test exists as two 
assays: a quantitative Elisa-based assay (BTA TRAK) and 
a qualitative POC test (BTA stat).
Only a small number of studies have investigated the 
role of BTA tests in the follow-up of patients with NMIBC 
(Table 3). The majority of these are phase II–III studies, 
although no study assessed the value of these tests in a 
decision-making process. Sensitivity and specificity have 
varied from 54 to 61% and from 74 to 86%, respectively 
[23–25]. These measures are affected by the presence of 
concomitant conditions such as stones and “benign” geni-
tourinary diseases [26]. Moreover, BTA tests have not been 
associated with future events such as Rec and Prog. Bell 
et al. compared the performances of different biomarkers 
and demonstrated that neither BTA STAT nor BTA Trak 
was associated with recurrence-free (RFS) or progression-
free survival (PFS) [19]. Due to the low sensitivity and 
high rates of false-positive results, use of BTA tests cannot 
be recommended for use in clinical routine.
ImmunoCyt/uCyt+ The ImmunoCyt test is an immunocy-
tological assay based on the microscopic detection of tumor 
cell antigens by immunofluorescence. The ImmunoCyt test 
measures the immunocytological expression of sulfated 
mucin-glycoproteins and glycosylated forms of the carci-
noembryonic antigen in urine. In patients presenting with 
painless hematuria, immunocytology improves the diagnos-
tic accuracy of standard predictive models by a clinically 
and statistically significant margin [27].
Sensitivity and NPV rates of ImmunoCyt vary between 
62–85% and 74–93%, respectively (Table 4). In 942 patients, 
Mian et al. found that the sensitivity increased with patho-
logic grade (79.3% for G1, 84.1% for G2 and 92.1% for G3 
tumors) [28]. In a prospective study, Bell et al. found no 
association of ImmunoCyt with either RFS or PFS [19]. The 
test is performed under microscopy and requires trained and 
experienced pathologists. Interobserver variability has been 
found to be a major drawback. The limited evidence of its 
benefit led to infrequent usage of the test [16].
UroVysion (FISH) UroVysion is a multicolor fluorescence 
in situ hybridization (FISH) containing probes to the cen-
tromeres of chromosomes 3, 7, 17 and the 9p21 locus (P16 
tumor-suppressor gene). Sensitivity and specificity rates in 
detecting Rec vary from 13 to 94% and from 63 to 100%, 
respectively (Table 5).
Despite this high variance in performance, several studies 
have suggested a clinical utility of FISH in specific clinical 
scenarios. Seideman et al. investigated the role of FISH in 
patients with previous BCa who presented at follow-up with 
both negative cytology and cystoscopy. In such cases, FISH 
was able to anticipate disease Rec at a median follow-up of 
26 months; mean time to Rec was 12.6 months in patients 
who were FISH positive compared to 17.9 months in those 
with negative FISH (p = 0.03) [15].
Another scenario for its use is the presence of an unsus-
picious cystoscopy and equivocal/atypical cytology or in 
patients with abnormal cystoscopy, in which the presence 
of cancer is not clear. In these patients, FISH could be used 
as a reflex test to adjudicate the significance of these find-
ings [14]. Two prospective studies have evaluated the role of 
FISH in the setting of atypical cytology or cystoscopy [29]. 
In these studies, a positive FISH had a high PPV and led to 
the recommendation to consider biopsy, upper tract imaging 
or close cystoscopic re-evaluation. Schlomer et al. reported 
a sensitivity and NPV of 100% [30]. In fact, based on these 
and other studies, the guidelines specifically recommend the 
use of a urine marker in this setting [31].
In terms of the predictive role of FISH, Kim et al. [32] 
reported the predictive role of FISH in NMIBC patients with 
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Table 2  List of studies investigating the performances of NMP22 tests in surveillance setting in non-muscle invasive bladder cancer patients
PPV positive predictive value, NPV negative predictive value, Rec recurrence, Prog progression, RFS recurrence-free survival, PFS progression-
free survival
Marker Author (year) refer-
ence








88 28 93.55 –
Grossman (2006) 
[66]
Cohort prospective 668 49.5 87.3 NPV 90.5%




Cohort 109 25 91.1 PPV 18.2%, NPV 
93.9%
Gupta (2009) [69] Cohort prospective 145 85.7 77.5 PPV 70.6%, NPV 
89.6%. association 
with rec
Kundal (2010) [70] Cohort 115 81.3 92 –
Choi (2010) [71] Cohort 262 72.7 91.7 –
Hwang (2011) [72] Cohort 597 22.6 97.9 –
Coskuner (2012) [73] Cohort 95 44.4 98.4 PPV 80%, NPV 92.6%
Önal (2015) [74] Cohort/case control 65 85.4 76.5 –
Yafi (2015) [17] Marker-comparison 
prospective
109 58 85 –
Bell (2016) [18] Marker-comparison 
prospective
91 – – Association with RFS 
and PFS
Lotan (2017) [7] Marker-comparison 
prospective
803 11 – NPV 86%
Pichler (2017) [19] Marker-comparison 
prospective
75 12.9 100 PPV 100%, NPV 
61.9%
NMP22 Serretta (1998) [75] Cohort 137 71 61 PPV 44.7%, NPV 83%
Witjes (1998) [76] Cohort 50 75 82 PPV 56%, NPV 91%
Serretta (2000) [77] Marker-comparison 
prospective
179 74 55 PPV 42.2%, NPV 83%





95 56 – –
Shariat (2004) [80] Cohort/case control 302/42 66 (cut-off 6.5 U/ml) 
54 (cut-off 10 U/
ml)
73 (cut-off 6.5 U/ml) 
85 (cut-off 10 U/
ml)






88 35 80.3 –
Lahme (2005) [81] Cohort/case control 
prospective
164/64 62 65.9 –
Kibar (2006) [82] Cohort/case control 
marker comparison
60/30 73 89.7 –
Raina (2008) [83] Cohort (atypical 
cytology)
71 81 89.3 PPV 92%, NPV 76%
Mansoor (2008) [84] Cohort 94 45 100 PPV 100%, NPV 87%
Horstmann (2009) 
[85]
Cohort 221 68 49 PPV 57%, NPV 60%
Shariat (2011) [20] Cohort (negative 
cytology)
2222 – – Association with Rec 
and Prog
Doğan (2013) [86] Cohort 49 33 76 PPV 31%, NPV 78%
Lotan (2017) [7] Marker-comparison 
prospective
803 26 – NPV 86%
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Table 3  List of studies investigating the performances of BTA tests in surveillance setting in patients with non-muscle invasive bladder cancer
PPV positive predictive value, NPV negative predictive value, RFS recurrence-free survival, PFS progression-free survival
Marker Author (year) reference Study design No. of patients Sensitivity 
(%)
Specificity (%) Other end points
BTA STAT Sarosdy (1995) [25] Cohort prospective/case–
control (separate)
499/564 40 96 –
Ianari (1997) [87] Cohort 75 54 91 –
Leyh (1997) [88] Cohort prospective 164 54 92 –
Hargreave (1997) [89] Cohort prospective 272 58 86 –
Sarosdy (1997) [90] Cohort retrospective/case–
control (separate)
220/550 67 29-95 –
Serretta (2000) [77] Marker-comparison retro-
spective
179 57 62 PPV 40%, NPV 76.9%
Giannopoulos (2001) Marker-comparison pro-
spective
95 72 – –
Sarosdy (2002) [91] Cohort/case–control (sepa-
rate)
438 50 – –
Lokeshwar (2002) [24] Cohort prospective 26 61 74 PPV 88%, NPV 38%
Raitanen (2008) Cohort prospective 501 56 86 –
Yafi (2015) [17] Marker-comparison pro-
spective
109 61 78 –
Bell (2016) [18] Marker-comparison pro-
spective
91 – – No association with RFS 
or PFS
BTA Trak Gutierrez Banoz (1999) 
[92]
Cohort 122 61 87 –
Serretta (2000) Marker-comparison retro-
spective
179 62 79 PPV 45.4%, NPV 88.4%
Sarosdy (2002) [91] Cohort/case–control (sepa-
rate)
438 50 – –
Fernandez Gomez 
(2002) [93]
Cohort Unknown (700 
samples)
62 68 –
Babjuk (2008) [22] Cohort prospective 88 54 84 –
Bell (2016) [18] Marker-comparison pro-
spective
91 – – No association with RFS 
or PFS
Table 4  List of studies investigating the performances of ImmunoCyt test in surveillance setting in non-muscle invasive bladder cancer patients
PPV positive predictive value, NPV negative predictive value, RFS recurrence-free survival, PFS progression-free survival





Vriesema (2001) [94] Cohort 86 50 73 PPV 39%, NPV 81%
Pfister (2003) [95] Cohort 458 70 82 –
Tetu (2005) [96] Cohort 904 74 62 PPV 26%, NPV 93%
Messing (2005) [97] Cohort 341 81 75 –
Lodde (2006) [98] Cohort 195 84 86 PPV 63%, NPV 92%
Mian (2006) [27] Marker-guided prospective 942 85 72 –
Sullivan (2009) [99] Cohort 100 76 63 PPV 43%, NPV 88%
Horstmann (2009) [85] Cohort 221 73 62 PPV 72%, NPV 74%
Yafi (2015) [17] Marker-comparison prospective 109 62 79 –
Bell (2016) [18] Marker-comparison prospective 91 – – No association with RFS or PFS
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negative cystoscopy and suspicious cytology in which posi-
tive FISH was a significant predictor of Rec (HR 2.35; 95% 
CI 1.42–3.90, p = 0.001) in multivariable analysis and for 
Prog (HR 3.01; 95% CI, 1.10–8.21, p = 0.03) in univariable 
analysis. It has further been shown that the decision to omit 
bladder biopsy because of negative UroVysion in patients 
with atypical cytology and negative or equivocal cystoscopy 
was cost-effective and may allow reduction of unnecessary 
adverse events [33].
Phase II–III markers
Cxbladder monitor Studies investigating the performance 
of this test are listed in Table  6. The Cxbladder Moni-
tor test is based on the detection of four mRNAs that are 
significantly increased in the urine of BCa patients and of 
another mRNA that is associated with non-malignant condi-
tions, included to reduce false-positive results. This marker 
panel was designed to optimize sensitivity. While this has 
improved test performance for this goal with reported sen-
sitivity and NPV of 93 and 97%, respectively, it does come 
at the cost of a low specificity [34]. Sensitivity reached 95% 
in recurrent disease with high risk of Prog, and false-neg-
ative findings were reported in only 1.5% of cases. These 
data have been successfully externally validated [7]. This 
test may allow clinicians to postpone or avoid cystoscopy in 
patients under surveillance, who are at low risk of Rec. This 
might lower the cost and potential morbidity while improv-
ing quality of life in these patients.
Bladder cancer test (UBC test) The Bladder Cancer Test 
(UBC) is available in two different assays. One is a quantita-
tive, ELISA-based assay (UBC IRMA) while the other is a 
qualitative POC-based assay (UBC Rapid). Both of these 
detect the presence of cytokeratins 8 and 18 in the urine 
which play an active role in tumor invasion. Sensitivity and 
specificity rates vary from 12 to 80% and from 77 to 92%, 
respectively. When performed in combination with cytol-
ogy, UBC has been reported to increase the overall sensitiv-
ity to 77.4% while decreasing its specificity [20]. Conversely 
to the other markers UBC is a point-of-care test, with results 
available within 10  min, and therefore, with possible and 
incontrovertible clinical advantages. However, the clinical 
utility of the UBC test in the follow-up of NMIBC patients 
remains unconvincing.
Phase I–II markers
XPERT BC monitor The XPERT Bladder Cancer (BC) Mon-
itor is an mRNA-based urinary marker test developed for 
BCa surveillance. It measures the levels of five different tar-
get mRNAs (ABL1, CRH, IGF2, UPK1B and ANXA10) by 
real-time PCR. These mRNAs are related to cell prolifera-
tion and survival, signal transduction and response to neu-
roendocrine stress. Advantages of the test are mainly related 
Table 5  List of studies investigating the performances of UroVysion test in surveillance setting in non-muscle invasive bladder cancer patients
PPV positive predictive value, NPV negative predictive value, Rec recurrence
Author (year) reference Study design No. of patients Sensitivity (%) Specificity (%) Other end points
Sarosdy (2002) [91] Cohort/case–control (separate) 438 71 94 –
Varella-Garcia (2004) [100] Cohort 19 87 100 –
Pycha (2004) [101] Cohort 49 35 86 –
Kipp (2005) [102] Cohort prospective 37 48 100 –
Bergmann (2007) [103] Cohort 41 77 93 PPV 83%, NPV 90%
Moonen (2007) [104] Cohort 105 39 90 –
Yoder (2007) [105] Cohort, reflex (negative cytology) 249 73 87 –
Gudjónsson (2008) [106] Cohort 159 30 95 –
Sullivan (2009) [99] Cohort 100 13 90 PPV 33%, NPV 72%
Horstmann (2009) [85] Cohort 221 76 63 PPV 68%, NPV 71%
Karnwal (2010) [107] Cohort 59 63 65 –
Schlomer (2010) [29] Cohort (atypical cytology and nega-
tive/equivocal cystoscopy)
73 100 67 PPV 21%, NPV 100%
Fritsche (2011) [108] Cohort (all HG) 25 94 93 PPV 76%, NPV 99%
Youssef (2012) [109] Cohort, reflex (negative cytology) 142 23 94 PPV 40%, NPV 88.5%
Kim (2014) [31] Cohort (negative cystoscopy, suspi-
cious cytology)
– – – Association with Rec
Sideman (2015) [14] Cohort, reflex (negative cystology and 
negative cystoscopy)
664 56 67 PPV 54.8%, NPV 67.9%
Lotan (2017) [7] Marker-comparison prospective 157 33 – NPV 92%
1988 World Journal of Urology (2018) 36:1981–1995
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to its rapidity (< 2 min of hands-on sample preparation and 
total PCR time of around 90 min). The first results of XPERT 
BC test have been recently reported [35]. In this study, a 
total of 155 urine samples of 140 patients with history of 
NMIBC were collected during routine follow-up. The test 
showed to be significantly superior to urinary cytology in 
terms of overall sensitivity (84 vs 33%) and NPV (93 vs 
76%), while overall specificity did not differ between tests 
(91 vs 94%). Moreover, while the sensitivity of the XPERT 
BC Monitor was 100% in patients with high-grade tumors, 
it remains relatively high (compared to cytology) also in 
patients with low-grade disease (77%). These findings are 
encouraging and call for prospective trials to go ahead in the 
test’s validation process.
Soluble FAS Soluble FAS (sFAS) is an antiapoptotic pro-
tein released by BCa cells, protecting them from host anti-
tumor activity. They are released in serum and urine, where 
they can be detected and measured by ELISA. Svatek et al. 
measured sFAS levels in 188 patients at risk for BCa Rec 
[36]. Higher levels of sFAS were associated with tumor 
stage ≥ T1, positive urinary cytology results and higher 
NMP22 levels. sFAS was more specific than NMP22 and 
was able to predict the presence of BCa in patients with 
negative cytology, suggesting that sFAS may be helpful as 
a complement to cytology. On multivariable analysis, sFAS 
levels predicted the presence of tumor (OR 3.1, CI 95% 1.6–
5.9) and invasive stage (OR 3.7, CI 95% 1.3–10.9). These 
results were confirmed by Yang and colleagues who found 
that sFAS levels were an independent predictor of RFS (HR 
1.4, 95% CI 1.1–1.9) [37]. However, the sFAS assay still 
needs to be refined and standardized prior to its introduc-
tion into clinical care. Moreover, further large, prospective, 
multicenter phase III trials are also needed.
Hyaluronic acid Hyaluronic acid (HA) is a non-sulfated gly-
cosaminoglycan that is involved in cell adhesion and pro-
liferation, promotes tumor metastasis, and has been shown 
to be elevated in a variety of tumors. It is degraded by hya-
luronidase enzyme (HAase) into small fragments that pro-
mote angiogenesis [16]. HA and HAase have been found to 
be elevated in the urine of BCa patients; they are measured 
with ELISA and RT-qPCR [38]. Lokeshwar et al. [25] per-
formed the HA–HAase test on 225 urine samples from 70 
BCa patients. Sensitivity, specificity, PPV and NPV were 91, 
70, 92 and 67%, respectively. In this study, the HA–HAase 
test demonstrated superior performance compared to the 
BTA Stat test. However, to date, this is the only published 
study focusing on the role of the HA test in the follow-up of 
NMIBC patients.
Survivin Survivin is an antiapoptotic protein that is almost 
exclusively expressed by malignant epithelium, which 
inhibits apoptosis, promotes cell proliferation, and induces/
enhances angiogenesis. Shariat et al. [39] evaluated levels 
of survivin and NMP22 in voided urine samples from 117 
BCa patients undergoing cystoscopy and 92 controls. Sur-
vivin had superior sensitivity (64%), specificity (93%), PPV 
(92%) and NPV (67%) compared to both NMP22 and urine 
cytology. Moreover, higher levels of survivin were associ-
ated with an increased risk of more advanced histologic 
grades [40]. While these findings are promising, this is the 
only published study evaluating the role of urinary survivin 
in the follow-up of NMIBC. Moreover, due to its low lin-
earity, the assay remains experimental and requires further 
development and standardization.
Telomerase Telomerase is a ribonucleoprotein that synthe-
sizes telomeres at the ends of chromosomes, thus ensur-
Table 6  List of studies investigating the performance of CXbladder monitor and UBC tests in surveillance setting in patients with non-muscle 
invasive bladder cancer
PPV positive predictive value, NPV negative predictive value
Marker Author (year) refer-
ence
Study design No. of patients Sensitivity (%) Specificity (%) Other end points
CXbladder monitor Lotan (2017) [7] Marker-comparison 
prospective
803 91 – NPV 96%
Kavalieris (2017) [33] Cohort prospective 763 93 – NPV 97%
Bladder cancer (UBC) 
test





95 80 – –
Babjuk (2008) [22] Cohort prospective 88 12 97 –
Pichler (2017) [19] Marker-comparison 
prospective (UBC 
qualitative)
75 61.3 77.3 PPV 65.5%, NPV 
73.9%
Pichler (2017) [19] Marker-comparison 
prospective (UBC 
quantitative)
75 64.5 81.8 PPV 71.4%, NPV 
76.6%
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ing genome stability. Several tumors, including BCa, show 
telomerase hyperactivity that protects the chromosomes of 
cancer cells and thereby produces potential immortality 
[16]. One study explored the role of telomerase in patients 
with previous diagnosis of NMIBC [41]. Brems et al. meas-
ured levels of telomerase in 123 patients with BCa (12 inci-
dent cancers and 111 follow-up visits) and found that higher 
telomerase levels were associated with Rec (sensitivity and 
specificity of 62 and 84%, respectively), and that combining 
telomerase with cytology led to an increased sensitivity, but 
to a decreased specificity in diagnosis when compared to 
cytology alone. The lack of specificity of telomerase activ-
ity makes it a biomarker of little value with a high false-
positive rate. Moreover, assays for telomerase still need to 
be standardized and validated.
Fibroblast growth factor receptor 3 (FGFR3) and  methyla‑
tion biomarkers About 70% of low-grade NMIBC has been 
found to harbor a mutation in the fibroblast growth factor 
three (FGFR3) gene [42]. Since this mutation seems to be 
able to identify a subgroup of patients with good progno-
sis [43], its analysis could serve as biomarker not only for 
the detection of recurrence during follow-up of low-grade 
cancers, but also to identify patients with a low risk of pro-
gression. Zuiverloon et al. determined the FGFR3 mutation 
status on 200 low-grade NMIBC patients [44]. The sensitiv-
ity of the assay for the detection of concomitant recurrence 
was 58%, while a FGFR3-positive test was associated with 
a 3.8-fold higher risk to have a recurrence during follow-up.
Several studies have explored the role of different DNA 
methylation genes as urinary biomarkers in the surveil-
lance setting. Actually, changes in DNA methylation are 
stable, tend to occur early during carcinogenesis and can 
be detected in cells released in urine. Methylation biomark-
ers’ performance seems to be highly variable depending on 
the studies. Su et al. analyzed the DNA methylation levels 
of six markers in 368 urine samples from 90 patients with 
NMIBC and reported a sensitivity and specificity of 89 and 
97%, respectively [45]. Similar findings were reported for 
other methylation markers [46, 47]. On the contrary, other 
studies did not confirm these promising findings: Abern 
et al. developed a PCR assay based on the methylation sta-
tus of TWIST1 and NID2. In a prospective surveillance trial, 
a relatively low sensitivity of 58% and specificity of 66% 
were reported [48]. Based on these results, methylation gene 
panels are, to date, far away to be implemented in routine 
clinical practice.
The combination of FGFR3 status and methylation bio-
markers has been tested with promising results initially. Beu-
kers et al. investigated the role of FGFR3 and of the meth-
ylation genes TERT and OTX1 in 977 NMIBC patients [49]. 
The combination of the three assays detected 57% of Rec 
with a specificity of 59%. The diagnostic value of FGFR3 
was limited in HG tumors, reflecting the lower percentage 
of its mutation in this subgroup of patients. FGFR3 muta-
tion was found to predict Rec over time: false-positive urine 
samples from patients with FGFR3 mutations were followed 
by a recurrence within 2 years in 73% of patients. Similarly, 
FGFR3 mutation in combination with a 3-plex methylation 
assay was found to have a sensitivity of 79% and a specific-
ity of 77% in detection of a tumor recurrence [50]. Finally, 
combining FGFR3 mutational status with methylation meas-
urement of a set of DNA methylation markers (HS3ST2, 
SEPTIN9 and SLIT2) led to a sensitivity/specificity/NPV 
of 94.5/75.9/98.5%, respectively, for detection of a recur-
rent tumor [51]. Combined analyses of FGFR3 mutation and 
DNA methylation markers could be valuable for risk stratifi-
cation of patients with NMIBC and for surveillance setting, 
providing the basis for a promising non-invasive urinary test.
Angiogenesis markers Vascular endothelial growth fac-
tor (VEGF) is associated with tumor angiogenesis and is 
secreted in urine by BCa cells. It is detectable and measur-
able with ELISA. High levels of urinary VEGF have been 
related to poor RFS in patients with previous NMIBC [52]. 
However, these preliminary data and the role of VEGF in a 
surveillance setting remain to be confirmed.
Others DNA microsatellites are short tandem DNA repeats 
resulting from a failure of DNA mismatch repair and are, 
therefore, involved in tumor cell transformation. They have 
been studied as urinary markers [53]. However, the low sen-
sitivity and specificity (58 and 73%, respectively) are not 
sufficient to recommend their implementation in clinical 
practice.
Finally, several other investigational biomarkers such as 
Ki-67, Fibronectin, CD44 antigen and BCa cell metabolites 
have been suggested to be related to the presence of BCa and 
have been studied in BCa detection [54]. However, their role 
in BCa surveillance remains uninvestigated or preliminary.
Urinary biomarkers for the prediction of BCG 
response
Performance criteria desired
The goal of urine markers in this specific scenario is to pre-
dict whether BCG treatment will be effective and to monitor 
its effectiveness.
Urinary markers rated according to quality 
of research—according to a phased approach
BCG efficacy appears to depend on the ability to generate 
an appropriate immune response, including mainly CD4 + T 
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cells and CD8 + cytotoxic T lymphocytes (CTLs) [55]. The 
therapeutic antitumor effect of intravesical BCG involves the 
interactive activity of urothelial cells (including BCa cells) 
and cells of the immune system. BCa cells are able to inter-
nalize BCG through phagocytosis and macropinocytosis. 
After this event, BCa cells directly secrete immune-activat-
ing effectors such as chemokines and cytokines (i.e., IL-6, 
IL-8, GM-CSF and TNF). Moreover, BCa cells are func-
tioning antigen-presenting cells, presenting BCG antigens 
to CD4 + T cells. BCa cells are finally killed by cytotoxic 
immune cells, secretion of soluble factors and the direct 
action of BCG [56].
Phase III–IV markers
According to AUA/SUO Guidelines, “clinicians may use 
biomarkers to assess the response to intravesical BCG 
 (UroVysion® FISH) and adjudicate equivocal cytology 
 (UroVysion® FISH and ImmunoCyt®)” [14]. UroVysion, 
performed 6 weeks after the last BCG instillation, was 
reported to predict BCG failure (either disease persistence 
or Rec), both in patients with positive urine cytology and in 
those with non-definitive cytology [57]. Abnormal results 
obtained from serial measurements of UroVysion at baseline 
(before BCG), at 6 weeks (before the last BCG induction 
cycle) and at 3 months (before the first surveillance cystos-
copy) were significantly associated with Rec and Prog. The 
term “molecular BCG failure” was proposed to define those 
patients with abnormal FISH results and negative first cys-
toscopy [58]. However, this concept remains to be validated.
Phase II–III markers
The presence and levels of BCG-induced cytokines in urine 
can be measured and might predict the clinical response 
to BCG. Kamat et al. [59] measured levels of 12 urinary 
cytokines and calculated changes from baseline during 
BCG treatment, developing a nomogram, based on nine 
inducible cytokines [IL-2, IL-8, IL-6, IL-1ra, IL-10, IL-
12(p70), IL-12(p40), TRAIL, and TNF-α] that could pre-
dict Rec with an accuracy of 85.5% (95% CI 77.9–93.1). 
Previously, several studies had focused on the role of urinary 
IL-2 levels in patients treated with BCG [60–62]. High lev-
els of IL-2 in urine after BCG administration were associ-
ated with increased risk of Rec. Similarly, elevated urinary 
levels of IL-8 and IL-18 after BCG therapy predicted RFS 
[63]. At a cut-off threshold of 112 pg/mL, IL-8 measured 
2 h after BCG instillation predicted Rec with a sensitivity 
of 53%, specificity of 89%, PPV of 73%, and NPV of 77% 
[64]. Finally, the IL-6/IL-10 ratio was able to predict BCG 
response and RFS in patients at intermediate risk with a 
sensitivity and specificity of 83 and 76%, respectively [65].
The suggested role of biomarkers involved in the predic-
tion of BCG response is summarized in Table 7.
Conclusions
Many urinary biomarkers have been evaluated to predict 
Rec and/or Prog in the follow-up of NMIBC patients. Cur-
rent commercially available urinary biomarker tests pro-
vide inadequate performance and are neither routinely used 
nor recommended in clinical practice. However, some of 
them could be useful in specific clinical scenarios such as 
a negative cystoscopy and inconclusive/suspicious urinary 
cytology. Moreover, preliminary results have shown that uri-
nary markers such as FISH might be useful to predict BCG 
response. Despite this, prospective well-controlled trials are 
lacking and are needed to provide high-evidence data before 
these tests can be integrated into clinical use.
Several new biomarkers have recently been developed 
and are currently under investigation. Despite encouraging 
Table 7  List of biomarkers predicting response to intravesical BCG in patients with non-muscle invasive bladder cancer
HR hazard ratio, CI confidence interval, PPV positive predictive value, NPV negative predictive value, CIS carcinoma in  situ, NMIBC non-
muscle invasive bladder cancer
Urinary biomarker Patients Outcome investigated Magnitude of effect Ref.
IL-2 CIS RFS HR 0.368; 95% CI, 0.029–0.895 [60]
IL-6/IL-10 High-risk NMIBC RFS HR 4.09; 95% CI 2.59–6.28 [64]
IL-8 Primary NMIBC Recurrence Sensitivity 53.3%, specificity 88.5%, PPV 
72.7%, NPV 76.7%
[63]
IL-18 NMIBC Recurrence Different IL-18 level’s statistical signifi-
cance in patients with or without recur-
rence
[62]
Nomogram [IL-2, IL-8, IL-6, IL-1ra, IL-10, 





Recurrence Accuracy 85.5%; 95% CI 77.9–93.1% [58]
UroVysion NMIBC Persistence or recurrence HR 5.6; 95% CI, 2.5–12.2 [56]
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results, their clinical relevance remains to be established. 
Most of them have not yet gone through all of the neces-
sary phases of marker development and the testing process. 
However, a renewed interest about biomarkers is growing 
and it is probable that in the next few years, a generation of 
new biomarkers will enter into the clinical setting.
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